Elan appoints chairman

Robert Ingram to succeed Kyran McLaughlin

Elan Corporation has appointed Robert Ingram, former chief executive of Glaxo Wellcome and former vice chairman of pharmaceuticals at GlaxoSmithKline, to the board effective immediately.

Ingram will also take up the role of chairman from 26 January 2011, succeeding Kyran McLaughlin, who in April announced his intention to step down as non-executive chairman following the completion of a search for a successor.

Since 2007, Ingram has been a general partner of venture capitalist Hatteras Venture Partners. He has also served as an advisor to the chief executive of GlaxoSmithKline since January 2010.

Elan is a neuroscience-based biotechnology company focused on developing therapies in neurodegeneration and autoimmune diseases. The company has two business units: BioNeurology, focused on Alzheimer's and Parkinson's diseases and multiple sclerosis; and Elan Drug Technologies (EDT), a drug delivery business, with more than a dozen programmes in late-stage development.

You may also like

Regulatory

Alkermes to initiate second Phase III study of ALKS 3831 for schizophrenia

ENLIGHTEN-2 will evaluate weight gain profile of novel, once-daily, oral investigational medicine compared with olanzapine
Regulatory

Alkermes initiates phase 1 clinical study of new CNS drug candidate

Novel, oral investigational medicine for the treatment of agitation in Alzheimer’s disease and other psychiatric indications
Regulatory

Alkermes achieves milestones for CNS medicines

Alkermes has announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases
Regulatory

Alkermes receives Notices of Allowance for US patents for four CNS pipeline candidates

Represent novel therapeutic approaches with potential to address unmet needs in their respective disease areas
Regulatory

Alkermes announces initiation of Phase 1 clinical study of ALKS 7106 for treatment of pain

Novel, investigational medicine designed to provide pain relief with intrinsically low potential for abuse and overdose death
Regulatory

Alkermes to initiate second Phase 2 clinical study of novel broad-spectrum oral antipsychotic

Study will evaluate efficacy, safety and tolerability of ALKS 3831 in patients with schizophrenia whose symptoms are exacerbated by alcohol use disorder
Research & Development

Alkermes to present data on new medicines in development for schizophrenia and depression

Results of positive Phase 3 study for aripiprazole lauroxil in schizophrenia to be presented at upcoming American Society of Clinical Psychopharmacology Annual Meeting
Subscribe now